(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.
The Cambridge-based pharmaceutical company said the Tagrisso treatment combined with chemotherapy, provided clinically meaningful benefits to lung cancer patients, demonstrating a statistically significant trend toward overall survival.
Results from the trial, which involved 557 patients, found consistent results across pre-specified subgroups, including sex, race, age at time of diagnosis, and smoking history.
The trial's principal investigator, Pasi Janne said: "These results further validate the importance of this additional treatment option, especially for those patients whose cancer has spread to the brain, those with L858R mutations, or other cause for poorer prognosis."
Tagrisso is already approved as monotherapy in more than 100 countries including in the US, EU, China and Japan. AstraZeneca will now continue to analyse the trial data as it matures over time.
Shares in AstraZeneca were up 2.5% to 10,418.00 pence in London on Thursday afternoon.
By Elijah Dale, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Astrazeneca (AZN)
